These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Disease activity as a major risk factor for osteonecrosis in early systemic lupus erythematosus. Fialho SC; Bonfá E; Vitule LF; D'Amico E; Caparbo V; Gualandro S; Pereira RM Lupus; 2007; 16(4):239-44. PubMed ID: 17439929 [TBL] [Abstract][Full Text] [Related]
4. Factors associated with osteonecrosis in Thai lupus patients: a case control study. Uea-areewongsa P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P J Clin Rheumatol; 2009 Oct; 15(7):345-9. PubMed ID: 20009970 [TBL] [Abstract][Full Text] [Related]
5. Aseptic necrosis and glucocorticosteroids in systemic lupus erythematosus: a reevaluation. Weiner ES; Abeles M J Rheumatol; 1989 May; 16(5):604-8. PubMed ID: 2666654 [TBL] [Abstract][Full Text] [Related]
6. Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. Goldberg RJ; Urowitz MB; Ibañez D; Nikpour M; Gladman DD J Rheumatol; 2009 Nov; 36(11):2454-61. PubMed ID: 19833754 [TBL] [Abstract][Full Text] [Related]
7. Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. Urowitz MB; Ibañez D; Gladman DD J Rheumatol; 2007 Jan; 34(1):70-5. PubMed ID: 17117488 [TBL] [Abstract][Full Text] [Related]
8. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Abeles M; Urman JD; Rothfield NF Arch Intern Med; 1978 May; 138(5):750-4. PubMed ID: 646538 [TBL] [Abstract][Full Text] [Related]
9. Risk factors for osteonecrosis in systemic lupus erythematosus. Mont MA; Glueck CJ; Pacheco IH; Wang P; Hungerford DS; Petri M J Rheumatol; 1997 Apr; 24(4):654-62. PubMed ID: 9101497 [TBL] [Abstract][Full Text] [Related]
10. Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. Dimant J; Ginzler EM; Diamond HS; Schlesinger M; Marino CT; Weiner M; Kaplan D J Rheumatol; 1978; 5(2):136-41. PubMed ID: 671430 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. Bessant R; Duncan R; Ambler G; Swanton J; Isenberg DA; Gordon C; Rahman A Arthritis Rheum; 2006 Dec; 55(6):892-9. PubMed ID: 17139666 [TBL] [Abstract][Full Text] [Related]
12. Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Nakamura J; Saisu T; Yamashita K; Suzuki C; Kamegaya M; Takahashi K Arthritis Rheum; 2010 Feb; 62(2):609-15. PubMed ID: 20112393 [TBL] [Abstract][Full Text] [Related]
13. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Compeyrot-Lacassagne S; Tyrrell PN; Atenafu E; Doria AS; Stephens D; Gilday D; Silverman ED Arthritis Rheum; 2007 Jun; 56(6):1966-73. PubMed ID: 17530722 [TBL] [Abstract][Full Text] [Related]
14. Role of specialty care in the management of patients with systemic lupus erythematosus. Urowitz MB; Kagal A; Rahman P; Gladman DD J Rheumatol; 2002 Jun; 29(6):1207-10. PubMed ID: 12064836 [TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease. Hochman J; Urowitz MB; Ibañez D; Gladman DD Lupus; 2009 Apr; 18(4):313-7. PubMed ID: 19276299 [TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors. Gladman DD; Dhillon N; Su J; Urowitz MB Lupus; 2018 Jan; 27(1):76-81. PubMed ID: 28530464 [TBL] [Abstract][Full Text] [Related]
17. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. Calvo-Alen J; Alarcon GS; Burgard SL; Burst N; Bartolucci AA; Williams HJ J Rheumatol; 1996 Mar; 23(3):469-75. PubMed ID: 8832985 [TBL] [Abstract][Full Text] [Related]
18. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. Abu-Shakra M; Urowitz MB; Gladman DD; Gough J J Rheumatol; 1995 Jul; 22(7):1265-70. PubMed ID: 7562756 [TBL] [Abstract][Full Text] [Related]
19. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. Ibañez D; Gladman DD; Urowitz MB J Rheumatol; 2005 May; 32(5):824-7. PubMed ID: 15868616 [TBL] [Abstract][Full Text] [Related]
20. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Calvo-Alén J; McGwin G; Toloza S; Fernández M; Roseman JM; Bastian HM; Cepeda EJ; González EB; Baethge BA; Fessler BJ; Vilá LM; Reveille JD; Alarcón GS; Ann Rheum Dis; 2006 Jun; 65(6):785-90. PubMed ID: 16269429 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]